University of Wisconsin, Madison
Division of University of Wisconsin
Latest From University of Wisconsin, Madison
Emerging Company Profile: Capitalizing on its proprietary platform technologies designed to develop high efficacy, disease-specific and low cost stem cell products, South Korea's SCM Lifescience aims to prove in clinical trials how its product candidates differ from existing stem cell therapies.
Fujifilm has successfully transformed its business strategy by expanding away from traditional photographic film and toward new priority business fields – significantly in regenerative medicine. Identifying health care as a key growth area, Fujifilm targets the role of being a comprehensive provider in the fields of prevention, diagnosis and treatment.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.
J&J Innovation's spate of deals led a busy week of deal-making involving many big pharmas. Sanofi exited its inhaled insulin partnership with MannKind, Merck collaborated with Quartet and Complix, Roche partnered with and helped finance C4, and Pfizer signed an immuno-oncology combo trial agreement with Syndax.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.